Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 890

1.

Using Standardized Interpretation of Chest Radiographs to Identify Adults with Bacterial Pneumonia-Guatemala, 2007-2012.

Wortham JM, Gray J, Verani J, Contreras CL, Bernart C, Moscoso F, Moir JC, Reyes Marroquin EL, Castellan R, Arvelo W, Lindblade K, McCracken JP.

PLoS One. 2015 Jul 24;10(7):e0133257. doi: 10.1371/journal.pone.0133257. eCollection 2015.

2.
3.

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to the 23-valent pneumococcal polysaccharide vaccine in elderly Japanese adults.

Shiramoto M, Hanada R, Juergens C, Shoji Y, Yoshida M, Ballan B, Cooper D, Gruber WC, Scott DA, Schmoele-Thoma B.

Hum Vaccin Immunother. 2015 Jul 15:0. [Epub ahead of print]

PMID:
26176163
4.

[Antibiotic Resistance and Serotype Pattern of Streptococcus pneumoniae Isolated from Children in St. Petersburg in 2010-2013].

Kalinogorskaya OS, Belanov SS, Volkova MO, Gostev VV, Sidorenko SV.

Antibiot Khimioter. 2015;60(1-2):10-8. Russian.

PMID:
26168680
5.

Additive impact of pneumococcal conjugate vaccines on pneumonia and empyema hospital admissions in England.

Saxena S, Atchison C, Cecil E, Sharland M, Koshy E, Bottle A.

J Infect. 2015 Jul 6. pii: S0163-4453(15)00222-4. doi: 10.1016/j.jinf.2015.06.011. [Epub ahead of print]

PMID:
26159503
6.

Despite High Cost, Improved Pneumococcal Vaccine Expected To Return 10-Year Net Savings Of $12 Billion.

Kohli MA, Farkouh RA, Maschio MJ, McGarry LJ, Strutton DR, Weinstein MC.

Health Aff (Millwood). 2015 Jul 1;34(7):1234-40. doi: 10.1377/hlthaff.2014.1274.

PMID:
26135209
7.

Pneumococcal disease prevention among adults: Strategies for the use of pneumococcal vaccines.

Pilishvili T, Bennett NM.

Vaccine. 2015 Jul 8. pii: S0264-410X(15)00787-2. doi: 10.1016/j.vaccine.2015.05.102. [Epub ahead of print] Review.

PMID:
26116257
8.

Impact of PCV7/PCV13 introduction on community-acquired alveolar pneumonia in children <5 years.

Greenberg D, Givon-Lavi N, Ben-Shimol S, Ziv JB, Dagan R.

Vaccine. 2015 Jun 23. pii: S0264-410X(15)00863-4. doi: 10.1016/j.vaccine.2015.06.062. [Epub ahead of print]

PMID:
26116251
9.

First Human Challenge Testing of a Pneumococcal Vaccine - Double Blind Randomised Controlled Trial.

Collins AM, Wright AD, Mitsi E, Gritzfeld JF, Hancock CA, Pennington SH, Wang D, Morton B, Ferreira DM, Gordon SB.

Am J Respir Crit Care Med. 2015 Jun 26. [Epub ahead of print]

PMID:
26114410
10.

Effectiveness of pneumococcal conjugate vaccine against presumed bacterial pneumonia hospitalisation in HIV-uninfected South African children: a case-control study.

Madhi SA, Groome MJ, Zar HJ, Kapongo CN, Mulligan C, Nzenze S, Moore DP, Zell ER, Whitney CG, Verani JR.

Thorax. 2015 Jun 19. pii: thoraxjnl-2014-206593. doi: 10.1136/thoraxjnl-2014-206593. [Epub ahead of print]

PMID:
26092924
11.

Pneumococcal Capsules and Their Types: Past, Present, and Future.

Geno KA, Gilbert GL, Song JY, Skovsted IC, Klugman KP, Jones C, Konradsen HB, Nahm MH.

Clin Microbiol Rev. 2015 Jul;28(3):871-899. Review.

PMID:
26085553
12.
13.

The ABC of pneumococcal infections and vaccination in patients with chronic kidney disease.

Vandecasteele SJ, Ombelet S, Blumental S, Peetermans WE.

Clin Kidney J. 2015 Jun;8(3):318-24. doi: 10.1093/ckj/sfv030. Epub 2015 May 7.

14.

Two or three primary dose regime for Haemophilus influenzae type b conjugate vaccine: meta-analysis of randomized controlled trials.

Thumburu KK, Singh M, Das RR, Jaiswal N, Agarwal A, Kumar A, Kaur H.

Ther Adv Vaccines. 2015 Mar;3(2):31-40. doi: 10.1177/2051013615575871. Review.

15.

Serological criteria and carriage measurement for evaluation of new pneumococcal vaccines.

Principi N, Esposito S.

Hum Vaccin Immunother. 2015 Jun 3;11(6):1494-500. doi: 10.1080/21645515.2015.1033600.

PMID:
25970715
16.

Prevention and treatment strategy in pregnant women with group B streptococcal infection.

Tevdorashvili G, Tevdorashvili D, Andghuladze M, Tevdorashvili M.

Georgian Med News. 2015 Apr;(241):15-23.

PMID:
25953932
17.

Cost-effectiveness of pneumococcal conjugate vaccination in Georgia.

Komakhidze T, Hoestlandt C, Dolakidze T, Shakhnazarova M, Chlikadze R, Kopaleishvili N, Goginashvili K, Kherkheulidze M, Clark AD, Blau J.

Vaccine. 2015 May 7;33 Suppl 1:A219-26. doi: 10.1016/j.vaccine.2014.12.070.

PMID:
25919165
18.

Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.

Vučina VV, Filipović SK, Kožnjak N, Stamenić V, Clark AD, Mounaud B, Blau J, Hoestlandt C, Kaić B.

Vaccine. 2015 May 7;33 Suppl 1:A209-18. doi: 10.1016/j.vaccine.2014.12.043.

PMID:
25919163
19.

Cost-effectiveness analysis of the introduction of the pneumococcal conjugate vaccine (PCV-13) in the Egyptian national immunization program, 2013.

Sibak M, Moussa I, El-Tantawy N, Badr S, Chaudhri I, Allam E, Baxter L, Abo Freikha S, Hoestlandt C, Lara C, Hajjeh R, Munier A.

Vaccine. 2015 May 7;33 Suppl 1:A182-91. doi: 10.1016/j.vaccine.2014.12.044.

PMID:
25919159
20.

Cost-effectiveness analysis of 10- and 13-valent pneumococcal conjugate vaccines in Peru.

Mezones-Holguin E, Canelo-Aybar C, Clark AD, Janusz CB, Jaúregui B, Escobedo-Palza S, Hernandez AV, Vega-Porras D, González M, Fiestas F, Toledo W, Michel F, Suárez VJ.

Vaccine. 2015 May 7;33 Suppl 1:A154-66. doi: 10.1016/j.vaccine.2014.12.039.

PMID:
25919156
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk